BMJ  2003;327:642 (20 September), doi:10.1136/bmj.327.7416.642

News

US politicians want federal funding to discover cost effectiveness of new drugs

Ray Moynihan

Washington, DC

The first 150 words of the full text of this article appear below.

A bill before the US Congress calls on health authorities to investigate whether expensive new drugs offer value for money, by comparing their risks and benefits with other treatments and older drugs.

Two members of the US House of Representatives, Jo Ann Emerson (Republican, Missouri) and Tom Allen (Democrat, Maine), are sponsoring a bill that would require federal funding for the evaluation of the cost effectiveness of new drugs

Credit: AP PHOTO/JOSE GOITA

Credit: AP PHOTO/PAT WELLENBACH

Currently new drugs are approved on the basis of their superiority over a placebo, with no requirement to show an advantage over existing treatments or cheaper generic pills.

If passed, the new legislation would see US taxpayers spending $75m (£47m; €67m) in 2004 to fund studies of the cost effectiveness of the nation's most expensive classes of drugs—something done routinely in other countries but a move that is bitterly opposed by the drug . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Articles

Federal funding for comparative drug studies not in US budget
Charles Marwick
BMJ 2004 328: 603. [Extract] [Full Text]

A bad week for drug companies?
Richard Smith
BMJ 2003 327: 0. [Extract] [Full Text] [PDF]

Access jobs at BMJ Careers
Whats new online at Student BMJ